EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Unraveling the Role of CYP2E1 in Antitubercular Drug–Induced Hepatotoxicity: From Molecular Mechanisms to Clinical Implications

Debasree Bishnu iD, Suman Santra iD, Swagata Purkait iD, Amal Santra iD

International Journal of Hepatology · 2025-01 · 2025 (1)

DOI: 10.1155/ijh/9980298 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Hepatology, online erschienen am 20.11.2025. Verfasst von Debasree Bishnu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Science and Disease Biology, John C. Martin Center for Liver Research & Innovations, Kolkata, West Bengal, India. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antitubercular (AT) drugs, particularly isoniazid (INH), rifampicin (RIF), pyrazinamide (PYZ), and ethambutol (EMB), are the cornerstone of tuberculosis (TB) treatment. However, their use is often limited by the risk of hepatotoxicity, a potentially severe side effect. Among the factors implicated in drug‐induced liver injury, cytochrome P450 2E1 (CYP2E1) is emerging as a key enzyme in the pathogenesis of hepatotoxicity. CYP2E1 is involved in the oxidative metabolism of many xenobiotics, including AT drugs, and is known to produce reactive oxygen species (ROS) during the metabolism process, which can lead to cellular damage. This review investigates the potential role of CYP2E1 in the mechanisms behind AT drug–induced hepatotoxicity and explores the biochemical and molecular pathways through which CYP2E1 might contribute to liver injury. Genetic polymorphisms in the CYP2E1 gene, which affect its activity, may also play a role in individual susceptibility to AT drug–induced hepatotoxicity. This review also deals with how multifactorial interactions including genetic polymorphisms in CYP2E1, N‐acetyl transferase 2 (NAT2), and glutathione‐S‐transferase (GST), as well as factors such as drug–drug interactions, nutritional status, coexisting infections (e.g., hepatitis B/C), and alcohol consumption collectively modulate individual susceptibility to AT drug–induced hepatotoxicity. By elucidating the role of CYP2E1 in AT drug–induced hepatotoxicity, this review provides a foundation for future therapeutic strategies, including the development of safer drug formulations or adjunct therapies targeting CYP2E1 to mitigate hepatotoxicity.

Schlagwörter

Stichwörter der Autor:innen

antitubercular drugscytochrome P450 2E1drug induced liver injurygenetic polymorphismhepatocellular damageoxidative stress

Autor:innen und Institutionen

  • Department of Basic Science and Disease Biology, John C. Martin Center for Liver Research & Innovations, Kolkata, West Bengal, India.
  • Department of Hepatology, Center for Liver Research, Institute of Post Graduate Medical Education & Research, Kolkata, West Bengal, India.

ORCID-Profile: Debasree Bishnu, Suman Santra, Swagata Purkait, Amal Santra

Zitieren

APA

Bishnu, D., Santra, S., Purkait, S., & Santra, A. (2025). Unraveling the Role of CYP2E1 in Antitubercular Drug–Induced Hepatotoxicity: From Molecular Mechanisms to Clinical Implications. International Journal of Hepatology, 2025(1). https://doi.org/10.1155/ijh/9980298

Vancouver

Bishnu D, Santra S, Purkait S, Santra A. Unraveling the Role of CYP2E1 in Antitubercular Drug–Induced Hepatotoxicity: From Molecular Mechanisms to Clinical Implications. International Journal of Hepatology. 2025;2025(1). doi:10.1155/ijh/9980298

BibTeX
@article{Bishnu2025,
  author = {Bishnu, Debasree and Santra, Suman and Purkait, Swagata and Santra, Amal},
  title = {Unraveling the Role of CYP2E1 in Antitubercular Drug–Induced Hepatotoxicity: From Molecular Mechanisms to Clinical Implications},
  journal = {International Journal of Hepatology},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/ijh/9980298}
}
Kostenlos starten →